Rho Proteins in Cancer
From the earliest stages of embryonic development through the metastatic spread of cancer cells, cell motility is a critical feature of life. The Ras homology, or Rho, family of small GTPases plays a broad and essential role in all stages of cell motility. Rac and Cdc42 remodel the actin cytoskeleton at the leading edge of the cell, resulting in membrane ruffles and protrusions, while Rho is largely responsible for orchestrating focal adhesion assembly and generating contractile forces at the rear of the cell, thus permitting cell movement across these adhesive contacts and subsequent detachment by the trailing end of the cell. Activation and inactivation of these small GTPases is modulated by a group of regulatory proteins - guanine nucleotide exchange factors (GEFs) activate, while GTPase activating proteins (GAPs) and guanine nucleotide dissociation inhibitors (GDIs) inhibit GTPase activity. Rho family proteins do not typically directly exert their effects on cell motility, but instead operate through a multitude of effector proteins, which each carry out a subset of motility-related functions. Because of their crucial roles in cell motility, Rho family protein expression and activation is altered in almost all types of cancer. As the body of knowledge surrounding Rho proteins, their interactions, and their regulation grows, so do the options for therapeutic intervention at an essential point of metastatic dissemination.
KeywordsHydrolysis Migration Lymphoma Tyrosine Leukemia
This work was supported by the Burroughs Wellcome Fund, the Breast Cancer Research Foundation, the Department of Defense Breast Cancer Research Program (BC083217 and BC083262), and the National Institutes of Health (CA-77612).
- Roof RW, Haskell MD, Dukes BD, Sherman N, Kinter M, Parsons SJ. Phosphotyrosine (p-Tyr)-dependent and -independent mechanisms of p190 RhoGAP-p120 RasGAP interaction: Tyr 1105 of p190, a substrate for c- Src, is the sole p-Tyr mediator of complex formation. Mol Cell Biol 1998 Dec;18(12):7052–63.PubMedGoogle Scholar
- van Golen KL, Davies S, Wu ZF, Wang Y, Bucana CD, Root H, et al. A novel putative low-affinity insulin-like growth factor-binding protein, LIBC (lost in inflammatory breast cancer), and RhoC GTPase correlate with the inflammatory breast cancer phenotype. Clin Cancer Res 1999 Sep;5(9):2511–9.PubMedGoogle Scholar
- Reuther GW, Lambert QT, Booden MA, Wennerberg K, Becknell B, Marcucci G, et al. Leukemia-associated Rho guanine nucleotide exchange factor, a Dbl family protein found mutated in leukemia, causes transformation by activation of RhoA. J Biol Chem 2001 Jul 20;276(29):27145–51.PubMedCrossRefGoogle Scholar
- Munugalavadla V, Sims EC, Borneo J, Chan RJ, Kapur R. Genetic and pharmacologic evidence implicating the p85 alpha, but not p85 beta, regulatory subunit of PI3K and Rac2 GTPase in regulating oncogenic KIT-induced transformation in acute myeloid leukemia and systemic mastocytosis. Blood 2007 Sep 1;110(5):1612–20.PubMedCrossRefGoogle Scholar
- Bourguignon LY, Gilad E, Rothman K, Peyrollier K. Hyaluronan-CD44 interaction with IQGAP1 promotes Cdc42 and ERK signaling, leading to actin binding, Elk-1/estrogen receptor transcriptional activation, and ovarian cancer progression. J Biol Chem 2005 Mar 25;280(12):11961–72.PubMedCrossRefGoogle Scholar
- Kusama T, Mukai M, Iwasaki T, Tatsuta M, Matsumoto Y, Akedo H, et al. Inhibition of epidermal growth factor-induced RhoA translocation and invasion of human pancreatic cancer cells by 3-hydroxy-3-methylglutaryl-coenzyme a reductase inhibitors. Cancer Res 2001 Jun 15;61(12):4885–91.PubMedGoogle Scholar
- Yao H, Dashner EJ, van Golen CM, van Golen KL. RhoC GTPase is required for PC-3 prostate cancer cell invasion but not motility. Oncogene 2005 Nov 28.Google Scholar